Optimizing the use of vilobelimab for the treatment of COVID-19

被引:4
作者
McCarthy, Matthew W. [1 ,2 ]
机构
[1] Weill Cornell Med, Dept Med, New York, NY USA
[2] Weill Cornell Med, Dept Med, 525 East 68th St, New York, NY 10065 USA
关键词
Complement; SARS-CoV-2; COVID-19; vilobelimab; C5a; Gohibic; COMPLEMENT; INFECTION; IMPROVES;
D O I
10.1080/14712598.2023.2235269
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: On 4 April 2023i4 April 2023, the United States Food and Drug Administration issued an emergency use authorization for the use of vilobelimab (Gohibic(TM)) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or extracorporeal membrane oxygenation. Areas Covered: Vilobelimab is a human-mouse chimeric IgG4 kappa antibody that targets human complement component 5a, a part of the immune system that is thought to play an important role in the systemic inflammation due to SARS-CoV-2 infection that leads to COVID-19 disease progression. Expert Opinion: A pragmatic, adaptive, randomized, multicenter phase II/III study evaluating vilobelimab for the treatment of severe COVID-19 found that patients receiving invasive mechanical ventilation and usual care who were treated with vilobelimab had a lower risk of death by day 28 and day 60 compared to those receiving placebo. This manuscript explores what is known about vilobelimab and explores how this treatment may be used in the future to treat severe COVID-19.
引用
收藏
页码:877 / 881
页数:5
相关论文
共 50 条
[21]   Use of Thiols in the Treatment of COVID-19: Current Evidence [J].
Mario Cazzola ;
Paola Rogliani ;
Sundeep Santosh Salvi ;
Josuel Ora ;
Maria Gabriella Matera .
Lung, 2021, 199 :335-343
[22]   Use of Integrative Treatment Methods by Individuals With COVID-19 [J].
Dogan, Nurhan ;
Fiskin, Gamze .
JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2022, 18 (05) :539-546
[23]   Use of baricitinib in treatment of COVID-19: a systematic review [J].
Sampath, Ananyan ;
Banerjee, Aditya ;
Atal, Shubham ;
Jhaj, Ratinder .
MEDICINAL RESEARCH REVIEWS, 2023, 43 (05) :1322-1345
[24]   COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract [J].
Ramasamy, Ranjan .
VIRUSES-BASEL, 2023, 15 (11)
[25]   Montelukast as a potential treatment for COVID-19 [J].
McCarthy, Matthew. W. W. .
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (05) :551-555
[26]   Emerging Technologies for the Treatment of COVID-19 [J].
Aghamollaei, Hossein ;
Sarvestani, Rahim ;
Bakherad, Hamid ;
Zare, Hamed ;
Guest, Paul C. ;
Ranjbar, Reza ;
Sahebkar, Amirhossein .
CLINICAL, BIOLOGICAL AND MOLECULAR ASPECTS OF COVID-19, 2021, 1321 :81-96
[27]   Impact of COVID-19 on Cardiovascular Patients and Review of Current COVID-19 Treatment Strategies [J].
Alfawaz, Dalal A. ;
Alfawaz, Mohammed ;
Almutawa, Ali M. .
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2020, 32 (42) :69-79
[28]   Gut microbiota in COVID-19 treatment [J].
Sadighpour, Tella ;
Tolouian, Audrey .
IMMUNOPATHOLOGIA PERSA, 2021, 7 (02)
[29]   Medical treatment options for COVID-19 [J].
Delang, Leen ;
Neyts, Johan .
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2020, 9 (03) :209-214
[30]   A role for retinoids in the treatment of COVID-19? [J].
Trasino, Steven E. .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (10) :1765-1767